Hillsdale Investment Management’s Voyager Therapeutics VYGR Stock Holding History

Hillsdale Investment Management’s Portfolio VYGR Stock Details VYGR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-367,590	Closed	-$2.85M	–	654
2023 Q3	$2.85M	Buy	367,590 +6,740	+2%	+$61.5K	0.26%	146
2023 Q2	$4.13M	Buy	+360,850	New	+$3.73M	0.38%	101
2023 Q1	–	Sell	-82,967	Closed	-$506K	–	653
2022 Q4	$506K	Sell	82,967 -5,000	-6%	-$28.4K	0.04%	336
2022 Q3	$521K	Buy	87,967 +68,300	+347%	+$437K	0.05%	316
2022 Q2	$116K	Buy	+19,667	New	+$133K	0.01%	419
2019 Q4	–	Sell	-37,000	Closed	-$637K	–	667
2019 Q3	$637K	Buy	+37,000	New	+$777K	0.06%	289

Other funds holding VYGR

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Hillsdale Investment Management's VYGR Position: Q4 2023 in Review

Hillsdale Investment Management sold out of Voyager Therapeutics (VYGR) in Q4 2023, closing a stake of 367,590 shares — an estimated $2.85M sold.

Hillsdale Investment Management first reported a position in VYGR in Q3 2019 and held it in 6 quarters. The position peaked at $4.13M in Q2 2023. 107 funds tracked by Wall St. Rank hold VYGR as of Q4 2023.

Hillsdale Investment Management reported no remaining Voyager Therapeutics position as of Q4 2023 after selling out during the quarter.
Hillsdale Investment Management sold 367,590 Voyager Therapeutics shares in Q4 2023, an estimated $2.85M.
Hillsdale Investment Management first reported a position in Voyager Therapeutics in Q3 2019 and held it in 6 quarters.
Hillsdale Investment Management's Voyager Therapeutics position peaked at $4.13M in Q2 2023.
107 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q4 2023.

Based on Hillsdale Investment Management's 13F filing for Q4 2023, filed 9 Feb 2024.